KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Amortization - Intangibles (2016 - 2026)

Pfizer has reported Amortization - Intangibles over the past 18 years, most recently at $1.2 billion for Q1 2026.

  • Quarterly Amortization - Intangibles fell 2.31% to $1.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.8 billion through Mar 2026, down 5.66% year-over-year, with the annual reading at $4.9 billion for FY2025, 7.79% down from the prior year.
  • Amortization - Intangibles was $1.2 billion for Q1 2026 at Pfizer, down from $1.2 billion in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $1.3 billion in Q3 2024 and troughed at $822.0 million in Q3 2022.
  • The 5-year median for Amortization - Intangibles is $1.2 billion (2025), against an average of $1.1 billion.
  • Year-over-year, Amortization - Intangibles dropped 15.08% in 2022 and then skyrocketed 44.04% in 2023.
  • A 5-year view of Amortization - Intangibles shows it stood at $822.0 million in 2022, then skyrocketed by 54.14% to $1.3 billion in 2023, then rose by 3.55% to $1.3 billion in 2024, then fell by 6.25% to $1.2 billion in 2025, then fell by 3.82% to $1.2 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Amortization - Intangibles are $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).